Clinical Trials/NCT06182410

NCT06182410WithdrawnPhase 2

Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy in Patients With High-Risk Neuroblastoma Receiving Tandem Transplants

University of California, San Francisco0 sitesStarted: August 1, 2024Last updated: August 7, 2024

Conditions

Interventions

Trial Snapshot

Phase: Phase 2
Status: Withdrawn
Sponsor: University of California, San Francisco
Primary Endpoint: Cumulative incidence of transplant-associated thrombotic microangiopathy (TA-TMA)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

This phase II trial tests how well defibrotide works in preventing transplant-associated thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing tandem transplants (hematopoietic stem cell transplant [HSCT]). TMA is a potential life-threatening complication of stem cell transplant. TMA is a possible side effect of the chemotherapy (conditioning regimen) patients receive to help treat high-risk neuroblastoma, because these medicines can sometimes damage the blood vessel walls in the body. This damage leads to formation of tiny blood clots in organs, especially the kidney. This then causes organ damage and leads to problems with how they function. This study may help researchers learn how defibrotide may help prevent TMA before it starts, or help treat it once it starts among patients with high-risk neuroblastoma undergoing tandem transplants.

Detailed Description

PRIMARY OBJECTIVE:

I. To determine if administration of prophylactic defibrotide sodium (defibrotide) will prevent the development of TA-TMA in participants with high-risk neuroblastoma receiving tandem transplants compared to historic controls.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of defibrotide in the prevention of severe TA-TMA, as defined by any TA-TMA with one or more of the following complications:

Ia. Renal failure requiring dialysis; Ib. Pleural or pericardial effusion requiring any surgical intervention; Ic. Central nervous system dysfunction, including seizure, posterior reversible encephalopathy syndrome (PRES); Id. Pulmonary hypertension; Ie. Biopsy-proven gastrointestinal involvement with bleeding; If. Death not related to relapse of underlying neuroblastoma; II. To determine the incidence of grade ≥ 3 hemorrhage (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) in participants on prophylactic defibrotide (grade 3 hemorrhage = transfusion indicated; invasive intervention indicated; hospitalization).

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Supportive Care
Masking: None

Eligibility Criteria

Ages: 1 Year to 18 Years (Child, Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Age: 1 - < 18 years old.
•Participants must have high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification at the time of initial diagnosis. Participants who were initially considered low or intermediate risk, but then reclassified as high risk are also eligible.
•Participants may have had salvage therapies (i.e., meta-iodobenzylguanidine (MIBG), dinutuximab) after induction but cannot have progressive disease at start of
•Planned tandem transplants with conditioning with cyclophosphamide-thiotepa and carboplatin-etoposide-melphalan on, or as per, NCT03126916 (ANBL1531) or other tandem-containing COG high-risk neuroblastoma trials.
•Participants may be enrolled in upfront neuroblastoma protocol, but this is not required.
•Upfront MIBG or other therapies is not a contraindication.
•Organ function per institutional standard of care (SOC) guiding clearance for autologous HSCT.
•Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria

•Life expectancy < 6 months.
•Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
•Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
•Known bleeding diathesis or bleeding risk deemed by the treating physician to be a contraindication to administration of defibrotide or on concomitant therapeutic anticoagulation. Administration of heparin and/or alteplase for central line maintenance is allowed.

Arms & Interventions

Supportive Care (defibrotide)

Experimental

Participants receive defibrotide IV over 2 hours every six hours on days -8 to +21 during the first and second rounds of Hematopoietic stem-cell transplantation (HSCT).

Intervention: Defibrotide (Drug)

Outcomes

Primary Outcomes

Cumulative incidence of transplant-associated thrombotic microangiopathy (TA-TMA)

Time Frame: Up to1 year

The cumulative incidence of TA-TMA in participants will be compared to historical controls. The historic controls will be participants with high-risk neuroblastoma who underwent planned tandem transplant at University of California San Francisco (UCSF) between 2017 and 2023.

Secondary Outcomes

Cumulative incidence of severe TA-TMA(Up to 1 year)

Investigators

Sponsor

University of California, San Francisco

Sponsor Class

Other

Responsible Party

Sponsor

Similar Trials

Active, not recruiting

Phase 2

Itacitinib for the Prevention of Graft Versus Host DiseaseHematologic and Lymphocytic Disorder

NCT04859946M.D. Anderson Cancer Center31

Terminated

Phase 2

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantChronic Graft Versus Host DiseaseHematopoietic and Lymphatic System Neoplasm

NCT06271616Mayo Clinic2

Completed

Phase 2

Defibrotide in COVID-19 PneumoniaPatients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure

NCT04335201IRCCS San Raffaele50

Withdrawn

Phase 2

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationAllogeneic Stem Cell Transplant RecipientHematologic and Lymphocytic DisorderHematopoietic and Lymphoid Cell Neoplasm

NCT04127721M.D. Anderson Cancer Center

Completed

Phase 2

NCT00089011Fred Hutchinson Cancer Center150